Q1 Results Surprise Driven by Dupixent's Strong Performance

Sanofi's Q1 net sales reached €10.5 billion (approximately $12.3 billion), a 6.2% increase year-over-year, exceeding Wall Street's expectations. This strong performance is largely attributed to the robust market penetration of Dupixent (dupilumab), an autoimmune disease treatment targeting the IL-4Rα receptor. Dupixent sales surged 31% year-over-year to €4.2 billion, surpassing market consensus by over 6%. This demonstrates Sanofi's leading position in the Immunology field, but also highlights an increasing reliance on a single product.

Recent Clinical Failures and Challenges in the R&D Pipeline

Despite the current growth momentum, Sanofi's drug pipeline faces medium- to long-term uncertainties due to consecutive setbacks in research and development (R&D). Specifically, tolebrutinib, a BTK inhibitor for multiple sclerosis, failed in a Phase 3 clinical trial last year and was rejected for FDA approval. Balinatunfib, an oral TNFR1 inhibitor, and itepekimab, a candidate for chronic obstructive pulmonary disease (COPD), also experienced consecutive failures in clinical trials. This quarter, the 5-valent meningococcal vaccine candidate SP0230 also failed to meet immunogenicity targets in a Phase 2 clinical trial, necessitating a revision of the development strategy.

Vaccine Business Unit's Resilience and Efforts to Diversify the Pipeline

Fortunately, the vaccine business, a traditional strength, recorded €1.3 billion in sales in Q1, partially mitigating market concerns. The recently launched Hepatitis B vaccine contributed to this performance. To address the upcoming patent expiration of Dupixent, Sanofi is actively seeking to acquire external pipeline assets. Key examples include efdoralprin alfa, an alpha-1 antitrypsin deficiency (AATD) treatment acquired from Inhibrx, and duvakitug, an anti-TL1A antibody co-developed with Teva. In addition, the company needs to expedite the clinical development of follow-up immunology assets, such as amlitelimab for atopic dermatitis, to overcome the patent cliff expected in the late 2020s.

Strategic Rigor Expected Under New CEO Belén Garijo

Sanofi's board of directors appointed Belén Garijo, from Merck KGaA, as the new CEO on May 1, following the departure of Paul Hudson, who had led the company for six years, and an interim period under Olivier Charmeil. Garijo is expected to implement unprecedented strategic rigor in Sanofi's R&D department, leveraging her experience in streamlining operations at Merck. Boosting the company's undervalued stock price and improving the success rate of new drug clinical trials are her top priorities. It is highly likely that she will implement more sophisticated clinical trial designs and make bold adjustments to the pipeline's priorities. The market is closely watching to see if she can reform the inefficient R&D structure and drive sustainable growth.